O'Neill A B, Brioni J D
Neuroscience Research, Pharmaceutical Products Division, Abbott Laboratories, IL 60064-3500.
Pharmacol Biochem Behav. 1994 Nov;49(3):755-7. doi: 10.1016/0091-3057(94)90097-3.
The anxiolytic-like effect of (-)-nicotine (1.9 mumol/kg, IP) on the elevated plus-maze in CD1 mice was blocked by the benzodiazepine receptor antagonist flumazenil (1 and 10 mumol/kg, IP). On the other hand, the cholinergic nicotinic channel blocker mecamylamine (1 to 15 mumol/kg, IP), did not affect the anxiolytic-like properties of diazepam in the same test. These data suggest that the reduction in anxiety induced by (-)-nicotine occurs indirectly via the release of endogenous substances that can activate the benzodiazepine receptor.